StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
PHX.AX$0.13+0.00%
Fair $0.13+0.0%

PHX.AX

PharmX Technologies Limited

Healthcare / Health Information ServicesASX

$0.13

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.13Fund rank 25/100 · Data gapFallback financials|
SA 41/C
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $1.6M · quality 43.7/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 9/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

41/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -1.7%, below the 5% threshold
Thesis & Journal · PHX.AXLocal privado en este navegador · PharmX Technologies Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$86M

P/E

N/A

•

EV/EBITDA

53.7x

↑

ROE

-1.7%

↓

Gross Margin

81.4%

↑

Debt/Equity

0.06

↓
52-Week Range$0
$0$0

TradingView lightweight chart

PHX.AX price, volumen y niveles de valoración

Último $0.130Periodo -92.4%
Fair value: $0.130

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-15.0%

FCF CAGR

—

FCF margin

-135.0%

FCF / Net income

37.44x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $7.3M · net income $-264000.0 · FCF $-9.9M

2022-FY → 2025-FY

Gross margin

81.4%-6.8% pts

Operating margin

-19.4%-22.3% pts

Net margin

-3.6%-5.7% pts

FCF margin

-135.0%-129.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$7.3M$7.3M$6.5M$6.0M$11.9M
Net Income$-264000.00$-264000.00$-1.8M$-1.1M$252000.00
EBITDA$1.4M$1.4M$1.4M$329000.00$2.5M
EPS-0.00-0.00-0.00-0.000.00
Gross Margin81.4%81.4%81.0%79.9%88.3%
Operating Margin-19.4%-19.4%-21.0%-12.9%2.9%
Net Margin-3.6%-3.6%-27.3%-17.5%2.1%
Balance Sheet
Debt/Equity0.060.060.020.000.01
Current Ratio3.683.68———
Cash Flow
Free Cash Flow$-9.9M$-9.9M$1.6M$7.6M$-694000.00
Returns
ROE-1.7%-1.7%-11.1%-4.7%1.1%
Valuation
P/E————95.00
EV/EBITDA53.6953.699.6928.336.78
P/B4.884.881.690.990.98
Growth & Yield
Revenue Growth12.8%12.8%7.8%-49.5%—
EPS Growth86.7%86.7%-66.7%-550.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +46.1%

Total return

+46.1%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.00 → -0.00

Residual

+46.1%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+46.1%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.